Exclusive Summary

• Distinct Broad-Spectrum Positioning: UB523 targets RdRp (RNA-dependent RNA polymerase), aiming to be a broad-spectrum antiviral treatment for respiratory infections.
• Validated Therapeutic Target: RdRp is a highly conserved and clinically validated target in antiviral drug development, potentially reducing mechanism-related risks.
• Early-Stage Partnership Opportunity: Currently in the preclinical research phase, offering an ideal entry point for overseas partners seeking co-development or early-stage pipeline expansion.